|
21 Companies |
|
22 Products |
|
22 Products |
|
21 Mechanisms of Action |
|
1 Trial |
|
58 News |
|
| 12» |
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial termination, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - May 1, 2019
P2, N=10, Terminated, Sponsor: Northwestern University
Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis
- | Trial completion date, Trial primary completion date: Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=234, Recruiting, Sponsor: Samsung Medical Center
Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020
- ||| nevanimibe (ATR-101) / Millendo Therap
Trial completion, Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Nov 6, 2017
P1, N=63, Completed, Sponsor: Millendo Therapeutics, Inc.
Trial completion date: May 2018 --> May 2024 | Trial primary completion date: May 2018 --> May 2020 Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016
- | Enrollment change, Trial termination, Trial primary completion date, Metastases: Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=6, Terminated, Sponsor: Burzynski Research Institute
Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016 N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment
- | veliparib (ABT-888) / AbbVie
Enrollment change, Trial withdrawal, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Sep 28, 2017
P1, N=0, Withdrawn, Sponsor: Vanderbilt-Ingram Cancer Center
N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment N=20 --> 0 | Not yet recruiting --> Withdrawn
- | veliparib (ABT-888) / AbbVie
Trial initiation date, Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Jul 19, 2017
P1, N=20, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=20 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Aug 2016 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed, Enrollment change, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - May 30, 2017
P2, N=10, Active, not recruiting, Sponsor: Northwestern University
Initiation date: Aug 2016 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Recruiting --> Active, not recruiting | N=33 --> 10
- | dovitinib (TKI258) / Allarity Therap, Oncoheroes
Trial completion, Metastases: Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma (clinicaltrials.gov) - Apr 25, 2017
P2, N=17, Completed, Sponsor: Spanish Oncology Genito-Urinary Group
Recruiting --> Active, not recruiting | N=33 --> 10 Active, not recruiting --> Completed
- ||| Trial completion: Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=97, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || nevanimibe (ATR-101) / Millendo Therap
Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Feb 7, 2017
P1, N=78, Recruiting, Sponsor: Millendo Therapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Feb 2019
- veliparib (ABT-888) / AbbVie
New P1 trial, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Jul 13, 2016
P1, N=20, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- Trial completion: EVACARNEY: Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC) (clinicaltrials.gov) - Jul 7, 2016
P=N/A, N=133, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Feb 2017 --> Feb 2019 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Studying Genes in Samples From Younger Patients With Adrenocortical Tumor (clinicaltrials.gov) - May 19, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - Apr 24, 2016
P2, N=33, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / Ono Pharma, BMS
New P2 trial, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - Mar 28, 2016
P2, N=33, Not yet recruiting, Sponsor: Northwestern University
- nevanimibe (ATR-101) / Millendo Therap
Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Feb 17, 2016
P1, N=78, Recruiting, Sponsor: Millendo Therapeutics, Inc.
Not yet recruiting --> Recruiting N=59 --> 78 | Trial primary completion date: Dec 2015 --> Feb 2017
- |||| selurampanel (BGG492) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Oct 7, 2015
P2, N=59, Completed, Sponsor: Novartis Pharmaceuticals
N=59 --> 78 | Trial primary completion date: Dec 2015 --> Feb 2017 Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015
- |||| TKM-PLK1 / Arbutus
Trial completion, Enrollment change, Metastases: A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients (clinicaltrials.gov) - Aug 28, 2015
P1/2, N=68, Completed, Sponsor: Tekmira Pharmaceuticals Corporation
Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed | N=56 --> 68
- || nevanimibe (ATR-101) / Millendo Therap
Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=59, Recruiting, Sponsor: Atterocor, Inc.
Active, not recruiting --> Completed | N=56 --> 68 Trial primary completion date: Jun 2015 --> Dec 2015
- Trial primary completion date: Studying Genes in Samples From Younger Patients With Adrenocortical Tumor (clinicaltrials.gov) - May 8, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Mar 2012 --> Jan 2100
- Avastin (bevacizumab) / Roche
Enrollment change: Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma (clinicaltrials.gov) - Apr 22, 2015
P2, N=0, Withdrawn, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Mar 2012 --> Jan 2100 N=24 --> 0
- Trial primary completion date: EVACARNEY: Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC) (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=133, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=24 --> 0 Trial primary completion date: Jan 2015 --> May 2015
- ||| TKM-PLK1 / Arbutus
Enrollment closed, Trial primary completion date, Metastases: A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients (clinicaltrials.gov) - Feb 24, 2015
P1/2, N=56, Active, not recruiting, Sponsor: Tekmira Pharmaceuticals Corporation
Trial primary completion date: Jan 2015 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Apr 2015
- |||| selurampanel (BGG492) / Novartis
Enrollment open, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Jan 8, 2015
P2, N=77, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Apr 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- Enrollment change, Trial primary completion date, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=9, Terminated, Sponsor: INSYS Therapeutics Inc
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014
- Trial termination, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=36, Terminated, Sponsor: INSYS Therapeutics Inc
N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014 Recruiting --> Terminated; Business decision by the sponsor during Phase 1.
- || nevanimibe (ATR-101) / Millendo Therap
Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Aug 21, 2014
P1, N=59, Recruiting, Sponsor: Atterocor, Inc.
Recruiting --> Terminated; Business decision by the sponsor during Phase 1. N=21 --> 59 | Trial primary completion date: Aug 2014 --> Jun 2015
- Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
Trial primary completion date, Surgery: Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery (clinicaltrials.gov) - Jun 17, 2014
P1, N=35, Completed, Sponsor: Mayo Clinic
N=21 --> 59 | Trial primary completion date: Aug 2014 --> Jun 2015 Trial primary completion date: Mar 2013 --> Jun 2013
- Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
Phase classification, Surgery: Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery (clinicaltrials.gov) - Jun 17, 2014
P1, N=35, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Mar 2013 --> Jun 2013 Phase classification: P=N/A --> P1
- | Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
Trial completion, Phase classification, Trial primary completion date, Surgery: Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery (clinicaltrials.gov) - Jun 17, 2014
P1, N=35, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | Trial primary completion date: Mar 2013 --> Jun 2013
- ||||| selurampanel (BGG492) / Novartis
New P2 trial: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - May 27, 2014
P2, N=77, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Trial completion date, Surgery, Metastases: Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 16, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | Trial primary completion date: Mar 2013 --> Jun 2013 Trial completion date: May 2012 --> Jun 2012
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2012 --> Jun 2012 N=160 --> 114
- cixutumumab (IMC A12) / Eli Lilly
Trial completion: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
N=160 --> 114 Active, not recruiting --> Completed
- || Enrollment closed: Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging (clinicaltrials.gov) - Feb 27, 2014
P=N/A, N=97, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (clinicaltrials.gov) - Feb 22, 2014
P2, N=180, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Germanin (suramin) / Optimum Therap
Trial completion, Metastases: Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Completed
- SVV-001 / Seneca Therap
Enrollment change: Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features (clinicaltrials.gov) - Jan 28, 2014
P1, N=22, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Completed N=51 --> 22
- | SVV-001 / Seneca Therap
Trial completion: Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features (clinicaltrials.gov) - Jan 28, 2014
P1, N=22, Completed, Sponsor: Children's Oncology Group
N=51 --> 22 Recruiting --> Completed
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Enrollment change, Surgery, Metastases: Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 6, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=44 --> 29
- ||| TKM-PLK1 / Arbutus
Enrollment change, Metastases: A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients (clinicaltrials.gov) - Sep 29, 2013
P1/2, N=56, Recruiting, Sponsor: Tekmira Pharmaceuticals Corporation
N=44 --> 29 N=42 --> 56
- cixutumumab (IMC A12) / Eli Lilly, Lysodren (mitotane) / HRA Pharma
Trial termination, Surgery, Metastases: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 29, 2013
P2, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
N=42 --> 56 Active, not recruiting --> Terminated; The trial was permanently halted due to futility concerns.
- cixutumumab (IMC A12) / Eli Lilly, Lysodren (mitotane) / HRA Pharma
Enrollment change, Surgery, Metastases: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 29, 2013
P2, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; The trial was permanently halted due to futility concerns. N=122 --> 20
- nevanimibe (ATR-101) / Millendo Therap
Enrollment open, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Aug 21, 2013
P1, N=21, Recruiting, Sponsor: Atterocor, Inc.
N=122 --> 20 Active, not recruiting --> Recruiting
- | nevanimibe (ATR-101) / Millendo Therap
New P1 trial, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Jul 10, 2013
P1, N=21, Recruiting, Sponsor: Atterocor, Inc.
- Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
Enrollment closed, Surgery: Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery (clinicaltrials.gov) - Apr 24, 2013
P=N/A, N=35, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Recruiting Completed --> Active, not recruiting
- New P1/2 trial, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Apr 14, 2013
P1/2, N=36, Recruiting, Sponsor: Insys Therapeutics Inc
- Inlyta (axitinib) / Pfizer
Trial completion, P2 data, Metastases: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer (clinicaltrials.gov) - Dec 27, 2012
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Recruiting --> Completed
- ||||||| linsitinib (ASP7487) / VasaraGen
Trial completion, Metastases: GALACCTIC: A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma (clinicaltrials.gov) - Oct 24, 2012
P3, N=139, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Active, not recruiting --> Completed